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 Microbial transglutaminase (MTG) is a practical tool to enzymatically form isopeptide 
bonds between peptide or protein substrates. This natural approach to crosslinking the side-
chains of reactive glutamine and lysine residues is solidly rooted in food and textile processing. 
More recently, MTG’s tolerance for various primary amines in lieu of lysine have revealed its 
potential for site-specific protein labeling with aminated compounds, including fluorophores. 
Importantly, MTG can label glutamines at accessible positions in the body of a target protein, 
setting it apart from most labeling enzymes that react exclusively at protein termini. To expand 
its applicability as a labeling tool, we engineered the B1 domain of Protein G (GB1) to probe the 
selectivity and enhance the reactivity of MTG towards its glutamine substrate.  We built a GB1 
library where each variant contained a single glutamine at positions covering all secondary 
structure elements. The most reactive and selective variants displayed a >100-fold increase in 
incorporation of a recently developed aminated benzo[a]imidazo[2,1,5-cd]indolizine-type 
fluorophore, relative to native GB1. None of the variants were destabilized. Our results 
demonstrate that MTG can react readily with glutamines in -helical, -sheet, and unstructured 
loop elements and does not favor one type of secondary structure. Introducing point mutations 
within MTG’s active site further increased reactivity towards the most reactive substrate variant, 
I6Q-GB1, enhancing MTG’s capacity to fluorescently label an engineered, highly reactive 
glutamine substrate. This work demonstrates that MTG-reactive glutamines can be readily 
introduced into a protein domain for fluorescent labeling.    
Introduction 
 For decades, microbial transglutaminase (MTG) from Streptoverticillium mobaraense has 
found widespread use in industries ranging from food preparation to textile processing and 
regenerative medicine.1 This breadth of applicability stems from two general characteristics: the 
first is its capacity to form amide bonds via the acyl-transfer reaction it catalyzes. In its native 
reaction, MTG catalyzes the reaction between the γ-carboxamide of a peptide- or protein-bound 
glutamine (referred to as the glutamine substrate) and the ε-amino group of a peptide- or protein-
bound lysine residue (referred to as the lysine substrate). Their conjugation produces isopeptide 
bonds – or protein crosslinks – for peptide and protein modification purposes (Fig. 1). The 
second characteristic is its robustness: MTG is relatively thermostable, co-factor independent, 
tolerant to organic co-solvents, and active over a range of pHs.2 These attributes make it possible 
to incorporate MTG into a wide array of reaction media and conditions.  
More recently, concerted efforts have been made to take advantage of MTG’s inherent ability 
to covalently modify proteins to further develop it as a tool for site-specific peptide and protein 
conjugation.3 Site-specific protein conjugation, which grants the researcher the ability to fine-
tune the properties of a protein post-translationally, is an area of intense research interest. Such 
modifications can modulate enzymatic activities, molecular interactions and recognition, or 
introduce functionalities that extend beyond the naturally-encoded chemistry.4 Among these, 
fluorescent labeling of biomolecules is of paramount interest.5-8 One of the foundations of this 
approach is to optimize the incorporation efficiency of the label onto a protein of interest. MTG 
has been applied for fluorescent labeling9-11 yet the determinants for its selective reactivity 
remains elusive. The deconvolution of these details holds great potential for improving MTG’s 
labeling capacity. 
Enzymes that are used to conjugate proteins are generally limited to using the N- or C-
terminus as the site of modification.12 The power of these enzymes stems from each enzymatic 
class having an amino acid recognition sequence that is targeted with high or exclusive 
selectivity, as long as this sequence is located at a protein terminus. Formylglycine generating 
enzyme, phosphopantetheinyl transferase, farnesyltransferase, biotin ligase, and lipoic acid ligase 
are examples of enzymes that catalyze such bioconjugations.12 As a recent example, 
formylglycine generating enzyme has been used to construct artificially glycosylated proteins,13 
and DNA-protein conjugates.14 
MTG differs from these enzymes, as its targeted residue does not need to be terminally 
located. This is advantageous as it allows for a label or modification to be introduced at any 
accessible, reactive position on the protein. MTG can thus serve as a labeling device for protein 
substrates that are not amenable to modification at their termini, or where internal modification 
of a protein is desired. Notable examples of MTG-catalyzed conjugation yielding applied protein 
products include the synthesis of antibody-drug conjugates15; 16 and PEGylation of 
pharmaceutically relevant proteins.17-19  
These successes result from MTG’s high promiscuity toward its lysine substrates,1; 3 with its 
ability to accept numerous primary amines being a key for the incorporation of diverse chemical 
functionality, such as bio-orthogonal functional groups to fluorophores. In contrast, MTG’s 
glutamine reactivity is restricted to protein- and peptide-bound glutamine residues. Phage display 
screening of glutamine-containing peptides has yielded several ‘glutamine tags’20 that were 
successfully applied to channel MTG’s reactivity during protein labeling;10 we note that this 
example used a C-terminally expressed glutamine recognition tag rather than a reactive 
glutamine internal to the target protein. Nonetheless, those glutamine-containing sequences are 
diverse in composition, revealing no clear pattern in the primary structure surrounding the 
reactive glutamine.20  
Further efforts made to elucidate MTG’s mode of substrate recognition include the 
elucidation of two crystal structures21; 22 as well as an alanine scan of its broad active site 
cavity.23 These have provided a greater understanding of the catalytic mechanism, kinetic 
parameters, and identifying key residues essential for activity yet did not clarify the 
characteristics of glutamine reactivity. An investigation of the impact of local secondary 
structure on glutamine reactivity comparing apomyoglobin, α-lactalbumin, and fragment 205-
316 of thermolysin concluded that unstructured regions strongly favored reactivity.24 Indeed, the 
majority of their multiple surface-exposed glutamines were not MTG-reactive. Consistent with 
this, we have observed no conjugation using the highly structured TEM-1 β-lactamase or E. coli 
asparaginase II as potential glutamine substrates, despite having 7 and 13 exposed glutamines, 
respectively (data not shown).  
In the face of a clear need to map glutamine reactivity relative to its molecular environment 
and design highly reactive glutamine substrates, here, we designed a tightly controlled system to 
investigate relative glutamine reactivity. Glutamine residues were introduced within a single 
framework, at various positions within elements of secondary and tertiary structure of the B1 
domain of Protein G (GB1). GB1 is a small self-folding domain of 6.2 kDa that has been 
extensively characterized as a model for protein folding and unfolding25 and can also be used to 
aid in soluble expression of small proteins.26 Native GB1 contains a single glutamine located on 
its unique α-helix (Fig. 2). We recently determined that MTG can conjugate GB1 at this 
residue;27 the efficiency of conjugation was poor, which we attributed to the glutamine belonging 
to a well-defined element of secondary structure. This presented us with the opportunity to use 
GB1 as a probe for investigating MTG’s glutamine reactivity and identifying more highly 
reactive locations for a glutamine residue, towards making MTG a more effective tool for protein 
conjugation. 
To this end, we employed a semi-rational approach28 to engineer both GB1 and MTG. We 
produced a library of 24 GB1 variants in which a single glutamine residue was introduced at 
various locations within its α-helix, loop structures, and β-sheet. We identified four GB1 variants 
that are at least 100-fold more reactive than native GB1; to our surprise, all belonged to well-
structured elements.  In parallel, based on previous mutagenesis results,23 we mutated three 
residues in the active-site area of MTG in the form of a small, focused library of six MTG 
variants. By those means, we identified one MTG variant that is significantly more reactive 
against native GB1 than native MTG. When tested against the most reactive GB1 substrate 
variant, two out of six MTG variants were observed to be 2.5-fold more reactive than native 
MTG. We thus demonstrate that highly MTG-reactive glutamines can be engineered into a well-
folded protein scaffold without regard to secondary structure location, and that MTG can be 
engineered to be more reactive towards its glutamine substrates. 
  
Results   
Design of the Single-Glutamine-Containing GB1 Variants 
Our objective was to compare the susceptibility of the different elements of secondary 
structure, namely -helices, -sheet, and unstructured loop elements to serve as backdrops for 
presenting a MTG-reactive glutamine. We targeted for mutagenesis a similar number of 
positions belonging to -helical, -sheet, and unstructured loop elements. A further criteria was 
that these positions were all solvent-exposed in the crystal structure (PDB ID: 3GB1). The 
crystal structure was visualized using PyMOL.20 Glycine residues were omitted out of concern 
that substitutions would perturb the structure. 
The first mutagenesis step consisted in replacing the sole native glutamine of GB1, Q32, 
with a structurally similar residue that MTG does not react with, asparagine. The Q32N knock-
out served not only as the template for generating future mutants, but as a negative control to 
verify that no conjugation was occurring at other sites on GB1. This was confirmed by resolving 
on gel and by high-resolution MS (Table S3). A single glutamine was then introduced at each of 
the 24 selected locations on the template. We confirmed that all the GB1 variants expressed 
solubly to similar levels as the native GB1 (Supporting Fig. 1). 
 
Fluorescent MTG Protein Assay 
The establishment of a sensitive assay to monitor the efficiency of labeling of the GB1 
variants was critical to the success of the study (Fig. 2). We and others previously investigated 
MTG’s ability to accept a variety of primary amines as substrates instead of lysine, and others 
have exploited this promiscuity as a tool to introduce diverse functionalities into proteins,29; 1; 15; 
30; 3 providing us with considerable flexibility in the choice of our probe. Our standard 
methodology for monitoring the products of MTG-catalyzed conjugation has been based on the 
use of liquid chromatography-mass spectrometry (LC-MS).31 However, visualizing and 
quantifying fluorescence output is more rapid and sensitive, and provides a direct means to 
screening for improved fluorescent protein labeling. To this effect, we recently reported a new 
class of highly tunable fluorescent compounds that can be readily functionalized to bear a 
primary amine.27 These bright fluorescent dyes are characterized by an unusually high 
excitation-emission differential and are highly soluble in aqueous media, making them good 
candidates for bioconjugation. Although the primary amine of benzo[a]imidazo[2,1,5-
c,d]indolizin-7-ylmethanaminium (1) is separated from the bulky, aromatic core by a single 
methylene, we have demonstrated that MTG can use it as a substrate to label two proteins, α-
lactalbumin (α-LA) as well as GB1; while α-LA is well established to be highly reactive with 
MTG,32; 33; 24 GB1 had not yet been known to be a substrate prior to our investigation.27 Here we 
extend this assay of fluorescent GB1 conjugation to the GB1 variants (Fig. 2). 
 While MTG reacts with micromolar concentrations of protein, millimolar concentrations 
of small-molecule reagents are generally required for the reaction to proceed effectively.22; 34 In 
the case of fluorescent labeling, use of fluorophore reagent 1 at a 100-fold excess relative to the 
GB1 protein substrates thus requires a means to remove excess unreacted 1, to prevent it from 
masking visualization on tricine SDS-PAGE. Using a 20-fold excess of 1 resulted in suboptimal 
yields (data not shown). Microdialysis proved to be effective at removing excess 1 for 
visualization.35 
 The quantification of fluorescence is described herein according to two properties: 
selectivity and efficiency (Table 1). Selectivity refers to the degree to which GB1 is labeled in 
the presence of MTG relative to non-specific binding. When non-specific binding of 1 was 
observed, as in the case of native GB1 and some of the GB1 variants (Fig. 3), the selectivity ratio 
was calculated; the lower the background, the higher the selectivity. Efficiency, instead, 
compares the fluorescent output of a labeled GB1 variant to that of the labeled native GB1; it 
expresses the relative reactivity of the glutamine. We observed that selectivity tended to increase 
as efficiency increased.  
 
Introduction of Glutamine into GB1 Loop Elements 
 Of the 24 glutamine-displaying GB1 variants prepared, eight of the targeted residues 
were located on flexible loops (Fig. 3), with at least one mutation being made in each of the four 
loops present in GB1. Based on the report of higher glutamine reactivity in disordered regions,24 
we anticipated that this subgroup of variants should be the most reactive. While T49Q exhibited 
good fluorescence following conjugation with 1, with both selectivity and efficiency well over 
one order of magnitude higher than native GB1, it was the only strongly improved loop variant. 
T11Q, located on a different loop, produced a modest increase compared to native GB1; all other 
loop variants were unreactive, or exhibited the same level of reactivity as the control lacking 
MTG (indicating non-specific binding of 1 to the GB1 variant). This is particularly surprising 
when closely observing the location of T49 within the crystal structure. Indeed, T49 is on the 
same loop as variants D47Q and A48Q; the former was inert to labeling, and A48Q was barely 
observable. These residues are all within a similar environment, making it difficult to rationalize 
the drastic difference in reactivity that MTG displays for its glutamine substrate. Similarly, the 
K10Q variant exhibited no reactivity despite being located beside T11 which, when substituted, 
was modestly more reactive than native GB1.  
We hypothesized that stability of the GB1 variant could affect the likelihood of a 
glutamine residue being tagged by MTG: if the introduction of a glutamine into GB1 destabilizes 
the structure, the disorder may correlate with increased accessibility. To this end, we determined 
the thermal melting point (Tm) of each variant using differential scanning fluorimetry (DSF; 
Table 2).36 DSF functions by the monitoring an increase in fluorescence upon binding of the dye, 
SYPRO Orange, to hydrophobic patches that become exposed as a protein unfolds. Variants that 
are more disordered should be less thermally stable, and display a lower Tm. The Tm calculated 
for all loop variants was essentially unchanged from the native GB1, allowing us to conclude that 
altered thermal stability of the variants is not a factor in the increased reactivity. These results 
indicate that there must be other determinants for glutamine reactivity beyond flexibility within 
its local environment. 
 
Relocating Glutamine in the α-Helix of GB1  
 Residue Q32 in native GB1 is located on the α-helix, with its side-chain exposed freely to 
the solvent (Fig. 2). Based solely upon solvent accessibility (and, presumably, accessibility for 
MTG), K28Q, K31Q, the native Q32 and N35Q would be expected to be the most reactive 
among the α-helix variants. Upon screening, only K31Q was among the most reactive while 
K28Q, the native Q32, and N35Q were among the least effective positions assayed. The 
immediate neighbor of K28Q, V29Q, is less exposed, yet it and K31Q were two orders of 
magnitude more selective and efficient than native GB1. This demonstrates that solvent 
exposition is not a strong predictor of reactivity. A22Q and D34Q are at opposite ends of the 
helix, and both exhibited similar, modest increases in selectivity and efficiency. Similarly to the 
loop variants, the Tm calculated for all α-helix variants was essentially unchanged from the 
native GB1. We thus demonstrate that the well-structured and tightly packed α-helix of GB1 can 
harbour highly MTG-reactive glutamines.  
 
Glutamines in the β-Sheet of GB1 Can Also Be Reactive 
 With the β-sheet being the largest single secondary structure element within GB1, over 
40 % of the newly introduced glutamines were located within it. Upon examining the crystal 
structure, we speculated that many of these mutations would react poorly, particularly those 
located on the internal β-strands 1 and 4 because they belong to a flat protein surface that does 
not appear to be complementary to the crevice that forms MTG’s active site (Fig. 4).23 This 
speculation was invalidated when the most selective and efficient variant was determined to be 
I6Q, located within β-strand 1. K4Q, the other variant introducing glutamine within β-strand 1, 
also exhibited high reactivity. T55Q also reacted strongly; that residue is located at the very edge 
of β-strand 4 and is not as tightly concealed within the structure as is I6Q. T17Q and E19Q lost 
reactivity, with the remaining four variants exhibiting activities on par with native GB1.  
These results are surprising, as MTG has been reported to prefer glutamine-containing 
regions that are predominantly unstructured,24 yet in the GB1 framework we observe the highest 
reactivity in α-helical and β-sheet regions. Therefore, secondary structure (or lack thereof) is not 
a strong predictor of glutamine reactivity. We attempted to identify patterns in the primary 
sequence flanking the reactive glutamines but failed to identify any potential markers to predict 
glutamine reactivity (Fig. 5). We also considered tertiary structure, seeking patterns in surface 
charge and hydrophobicity (Supporting Figs. 2-4), as well as B-factors (Supporting Fig. 5). No 
clear sequence or structural pattern or trend was observed amongst the reactive glutamines, 
making it difficult to predict where MTG will bind. 
 
Active-site Mutations in MTG Increase Reactivity Towards the Glutamine Substrate 
Having obtained highly reactive glutamine variants of GB1 towards MTG-catalyzed 
conjugation, we sought to further improve the performance of MTG toward these GB1 
substrates. There is a shortage of data indicating which residues play a role in binding MTG’s 
glutamine-containing substrate. Among the most informative works is an alanine scan of 29 
active-site residues, constituting 9 % of the apoenzyme’s amino acid sequence.23 A number of 
residues were found to be critical for activity, crippling MTG when substituted for alanine. Some 
alanine substitutions, however, resulted in an increase in activity, including the highly conserved 
W69 and the conserved Y75 and Y302. We selected these three aromatic residues for 
mutagenesis, introducing histidine as a semi-conservative modification (aromatic yet smaller and 
more hydrophilic), or glycine as a potentially more disruptive modification, ultimately yielding 
six MTG point mutants.  
Upon purification of the MTG variants, we verified activity using the standard hydroxamate 
assay with the Cbz-L-glutaminylglycine (ZQG) protected dipeptide substrate.37 All six variants 
were not only active, but exhibited higher activity for ZQG than did native MTG (Table 3). This 
is consistent with observation of increased activity in the corresponding alanine variants.23 
Y302G displayed the greatest improvement, being nearly 3-fold more active. Despite this 
increase in activity toward ZQG, when the variants were assayed against native GB1, half were 
observed to have very modest increases in efficiency and selectivity, with both Y302 variants 
falling into this group (Table 4). When compared to the reactivity of native MTG, both Y75 and 
W69G substitutions decreased the conjugation efficiency.  
Building on these findings, we proceeded to assay the variants against the most reactive GB1 
protein, I6Q. The W69 and Y75 MTG variants were all less active than native MTG, but both 
Y302G and Y302H MTG variants were moderately more active than native MTG, as had been 
the case when assayed against native GB1. When the efficiency of the six MTG variants on I6Q 
was compared to native GB1, they were all between one and two orders of magnitude more 
reactive towards I6Q GB1, maintaining the trend that I6Q GB1 is more reactive to labeling than 
native GB1. 
The high reactivity of I6Q GB1 resulted in rapid saturation of the fluorescence signal after 
the exposure time we had determined to be optimal for quantification of most variants (5 s). To 
compare the reactivity of MTG and its variants more accurately, we recorded the fluorescent 
signal after 1 s of exposure, where saturation was not observed (Table 4). Three MTG variants, 
W69H, Y302G, and Y302H, reacted with I6Q GB1 as well as or better than native GB1. W69H 
maintained the same level of reactivity as native MTG, where Y302G and Y302H were twice as 
efficient. Taken together, these results demonstrate that engineered MTG and GB1 variants can 
be paired to create an effective protein labeling system: it is possible to engineer both the 
substrate and the catalyst towards higher efficiencies, and these effects of engineering the 
substrate and the enzyme are cumulative. 
 In summary, among a library of 24 different glutamine-containing point mutations, 
covering 43 % of the amino acid sequence, four GB1 variants were observed to be at least 100-
fold more reactive towards MTG and four more were at least 10-fold more reactive. Thus, one-
third of the glutamines tested in the well-folded, globular GB1 protein provided good substrates 
for MTG labeling, with the I6Q substitution being the most reactive among all. We were not able 
to identify any clear trend that MTG displays towards the environment in which the glutamine 
residue is located, whether considering the primary sequence flanking the glutamine (Fig. 6) or 
tertiary structure properties (Supporting Figs. 2-4). We initially expected that loop variants 
would be the most reactive, as the high flexibility of these elements would make them the most 
likely candidates to fit into MTG’s active-site cleft. However, the loop variants underperformed 
relative to α-helix or β-sheet variants, leading us to hypothesize that if secondary structure plays 
a role in MTG’s substrate recognition, there are other, more important factors that dominate 
MTG’s glutamine selectivity. If MTG undergoes a significant structural rearrangement upon 
binding to its glutamine-bearing protein substrate, as does its mammalian TG2 counterpart,38 
then predicting their mode of interaction may require their co-crystallization.  
 To conclude, through a semi-rational approach, we constructed and improved a protein 
labeling system in which both the catalyst and substrate were optimized. Enzymatic 
bioconjugation is advantageous over traditional chemical modifications owing to increased 
selectivity displayed by enzymes,12 with MTG’s glutamine selectivity being central to its 
effective application. MTG has the advantage of being independent of an N- or C-terminal 
reactive site, which is a requirement for most enzymes used for protein labeling, allowing for 
increased selection and flexibility of the modification site within the protein target. In addition, 
as we have demonstrated, MTG labeling activity has the potential to be improved by protein 
engineering. Point mutations improved the reactivity of the substrate protein, GB1, by over two 
orders of magnitude, which was further enhanced when coupling with variants of the catalyst, 
MTG. Through this process, we probed the selectivity MTG displays for its glutamine-bearing 
protein substrate. Although no clear recognition pattern was observed, we have demonstrated the 
straightforward engineering of MTG-reactive glutamines in a well-folded domain, suggesting 
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Materials and Methods 
Materials 
The plasmid pDJ1-3 was kindly provided by Professor M. Pietzsch (Martin-Luther-
Universität, Halle-Wittenberg, Germany). pDJ1-3 encodes the proenzyme of MTG from S. 
mobaraensis inserted between the NdeI and XhoI restriction sites of the vector pET20b.39 The 
plasmid pQE80L-CysGB1Cys was kindly provided by Professor Hongbin Li (University of 
British Columbia, Vancouver, Canada). pQE80L-CysGB1Cys encodes GB1 with an N-terminal 
poly-histidine tag inserted into the BamHI restriction site of the vector pQE80L. The plasmid 
also encodes an extra cysteine residue present just before and after the open reading frame of 
native GB1. The sequence served as a template for amplifying the native GB1 coding sequence. 
Deionized water (18Ω) was used for all experiments. Products used for the expression and 
purification of MTG and GB1 were of biological grade.  
Other chemicals used were purchased from the suppliers listed below. Carboxybenzyl–L-
glutaminyl–glycine (Z-Gln-Gly, or ZQG) was from Peptide Institute (Osaka, Japan). Glutathione 
(reduced) and thiamine were from Bioshop (Burlington, Canada). Dimethyl sulfoxide (99.7%) 
was purchased from Fisher Scientific (Ontatio, Canada).  Formic acid (98 % purity) was from 
Fluka Analytical (St. Louis, USA). FastDigest NdeI, BamHI, DpnI, Phusion® High-Fidelity 
Polymerase and Fast AP Thermosensitive Alkaline Phosphatase were purchased from 
ThermoFisher Scientific (Waltham, MA, USA). Takara T4 DNA Ligase was purchased from 
Clontech (Mountain View, CA, USA). FastBreak™ Cell Lysis Reagent was purchased from 
Promega (Madison, WI, USA). 
 
Expression and purification of MTG 
 MTG was expressed and purified as previously described.30 Briefly, a 5-mL starter 
culture of E. coli BL21 (DE3) containing the plasmid pET20b-MTG, which expresses a C-
terminally 6-His-tagged version of MTG, was propagated overnight at 37°C in ZYP-0.8G 
medium and shaking at 240 rpm. It was used to inoculate 500 mL of auto-inducing ZYP-5052 
medium.40 After 2 h of incubation at 37°C and 240 rpm, the temperature was reduced to 22°C 
overnight. Cells were collected by centrifugation and resuspended in 50 mM sodium phosphate 
buffer, 300 mM NaCl, pH 7.5. The cells were lysed using a Constant Systems cell disruptor set 
at 37 kPSI and cooled to 4°C. After further centrifugation to remove insoluble cellular matter, 
the inactive form of MTG was incubated with trypsin (1 mg/mL solution, 1:9 ratio of trypsin to 
MTG, v/v) for the purpose of cleaving its pro-sequence. Activated MTG was purified using a 5-
mL His-trap nickel-nitrilotriacetic acid (Ni-NTA) column (GE Healthcare) equilibrated in 50 
mM phosphate buffer, pH 7.5, with 300 mM NaCl, and eluted with an imidazole gradient (0 – 
250 mM) using an Åtka FPLC (GE Healthcare). After purification, active MTG was dialyzed 
against 50 mM sodium phosphate buffer, 300 mM NaCl, pH 7.5. The average yield was 25 mg 
of activated MTG per litre of culture, with ~ 85% purity as estimated by SDS-PAGE and 




 Plasmid pDJ1-3, encoding the open reading frame for MTG, was used as a template for 
mutagenesis. All mutants were obtained using the rolling circle approach.41; 42 Following 
mutagenesis with Phusion® High Fidelity polymerase, the amplified PCR product was treated 
with FastDigest DpnI before being transformed into E. coli BL21 (DE3) for protein expression. 
Ampicillin (Amp) was used at 100 µg/mL for plasmid maintenance. Sequences were confirmed 
by DNA sequencing (ABI 3730 DNA sequencer, IRIC Genomic Platform at Université de 
Montréal). (Table S1).  
 
Expression and purification of native GB1 and variants 
A 2-mL starter culture of E. coli BL21 (DE3) containing the plasmid pET15b-GB1, or 
mutagenized plasmids expressing a variant within the same vector, which expresses an N-
terminally 6x-His-tagged version of GB1, was propagated overnight at 37°C in LB medium 
containing 100 µg/mL ampicillin and shaking at 240 rpm. A 500 µL volume of the starter culture 
was used to inoculate 50 mL of LB medium containing 100 µg/mL ampicillin. After 3h of 
incubation at 37°C and 240 rpm, IPTG was added to a final concentration of 0.2 mM and 
expression was allowed to proceed for 3 hours. Cells were collected by centrifugation and 
resuspended in 2.7 mL of 50 mM sodium phosphate buffer, 300 mM NaCl, pH 7.5. FastBreak™ 
cell lysis reagent was added to the resuspended cells to a final volume of 3 mL, mixed by 
inversion, and incubated at room temperature for 10 min. After further centrifugation at 4°C to 
remove insoluble cellular matter, the clarified lysate was loaded onto 1 mL of nickel-
nitrilotriacetic acid (Ni-NTA) resin (GE Healthcare) equilibrated in 50 mM phosphate buffer, pH 
7.5, with 300 mM NaCl. The resin was washed with 10 column volumes of the same buffer 
containing 15 mM imidazole, and eluted in 3 mL using the phosphate buffer containing 250 mM 
imidazole. After purification, GB1 was dialyzed against 50 mM sodium phosphate buffer, pH 
7.5, 300 mM NaCl, 1 mM EDTA. The average yield was 3 mg of GB1 per 50 mL of culture, 
with ~ 90% purity as estimated by tricine SDS-PAGE35 and revelation with Coomassie blue 
stain. Aliquots were snap frozen and stored at -80°C in 20% glycerol. 
 
GB1 Mutagenesis 
The pET15b-GB1 plasmid encoding the open reading frame for GB1 was used as a 
template for mutagenesis. The sequence for glutamine knock-out, Q32N, was generated first 
from native GB1, and was subsequently used as a template for amplification of all other GB1 
mutants. Site overlap extension was used to generate mutant GB1 sequences.43 The DNA 
fragments were digested with FastDigest NdeI and BamHI restriction enzymes, and religated into 
pET15b which had been cut with the same enzymes and also dephosphorylated, and transformed 
in E. coli BL21 (DE3).  
 
MTG Activity Assay 
The activity of purified MTG was quantified using the hydroxamate assay.37 Briefly, 
MTG was incubated with 30 mM Z-Gln-Gly and 100 mM hydroxamate at 37°C for 10 min. A 
concentrated acidic ferric chloride solution (2.0 M FeCl3 ∙ 6 H2O, 0.3 M trichloroacetic acid, 0.8 
M HCl) was used to quench the reaction in a 1:1 ratio (v/v) to the reaction, which was then 
vortexed and left to stand at room temperature for 10 min. The resulting iron complex was 
quantified by its absorbance at 525 nm, using the molar extinction coefficient 525 nm. One unit 
(U) of MTG produces 1 μmol of L-glutamic acid and γ-monohydroxamate per min at 37°C. 
 
Fluorescent conjugation assays 
Purified GB1 variants were quantified by measuring the A280, using a molar extinction 
coefficient of 9970 M-1cm-1 as calculated using ExPASy’s ProtParam module. Native GB1 or its 
variants (50 µM) were combined with 5 mM fluorophore 1 and 2.5 mM glutathione. The 
conjugation reaction was initiated by the addition of 2 U/mL of MTG, where control reactions 
had an equivalent volume of buffer (100 mM sodium phosphate, pH 7.5) added instead. The final 
volume of each reaction was 150 μL and all were incubated at 37°C for 24 h. Aliquots of 50 μL 
were taken after 2 h, 6 h, and 24 h of reaction time, and quenched with the addition of 2 μL 
formic acid. Excess, unreacted fluorophore was removed by dialysis using a Pierce™ 96-well 
microdialysis plate with a 3.5 kDa MWCO (ThermoFisher). To this effect, aliquots of 50 μL 
were dialyzed against three exchanges of 2 mL of buffer (100 mM sodium phosphate, 300 mM 
NaCl, 1 mM EDTA, pH 7.5) at 4°C. 
 
High resolution mass spectrometry 
Aliquots taken at 24 h were centrifuged to remove any insoluble matter, and transferred 
to LC-MS vials. Undiluted samples (5 μL) were injected without any additional treatment onto 
an Aeris peptide XB-C18, 3.6-μm, 150 × 2.1 mm LC column (Phenomenex) and eluted with a 
16-minute, 5-50% ACN/H2O gradient. Masses were detected under positive ionization (ESI) 
with a Synapt G2S (Q-TOF) triple quadrupole mass detector (Waters). 
 
Differential Scanning Fluorimetry 
 Melting temperatures of GB1 proteins was determined using a LightCycler ® 480 real-
time PCR platform (Roche) by thermally-induced incorporation of SYPRO Orange into the 
unfolding protein, as previously described.36 Briefly, 6.66 × SYPRO Orange solution 
(Invitrogen) with 8 μM test protein was probed in a 96-well LightCycler plate (Sarstedt). 
SYPRO Orange and the protein were diluted with 50 mM sodium phosphate, pH 7.5, to a final 
volume of 20 μL per well. Controls contained SYPRO Orange in buffer. The plates were sealed 
using Optically Clear Sealing Tape (Sarstedt) and heated from 20°C to 95°C with a ramp speed 
of 0.04°C/sec and 10 acquisitions/°C. Fluorescence was monitored with a CCD camera, using 
λexc = 483 nm and λem = 568 nm and a 1 s exposure time. Any curve showing a maximum 
fluorescence plateau during denaturation was excluded from the Tm calculation. 
For the Tm calculations, both temperature and fluorescence data were smoothed.44 The 
first derivatives dFluo or dTemp were calculated using the cubic spline interpolation. The 
preliminary maximum was determined to obtain the half-values to the left and right of it. The 
linear fit for the curve outside the half-values was calculated, followed by the calculation of the 
average deviation from the fit. If the maximum was below the detection limit (fit value + 3 × 
deviation), the Tm determination was considered uncertain. The quadratic fit around the 
maximum was then calculated as follows to obtain Tm. The first derivative of the quadratic fit 
function (y-value) was set to 0 and the x-axis value (temperature) was resolved. Then, the 
average deviation of the curve points around the maximum from the quadratic fit was calculated. 
If the relative deviation was greater than 5%, the Tm values were rejected if the corresponding 
maximum was below the detection limit. However, Tm values with a maximum above the 
detection but a relative deviation greater than 5% were defined as uncertain. 
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Mutation Selectivity Efficiency 
α-helix Native 1.3 1 






K10Q N.D. N.D. 
T11Q 16 4 
V21Q 1.2 - 
D40Q 3.9 - 
E42Q 4.2 - 
D47Q N.D. N.D. 
A48Q 1.0 - 





A24Q 5.0 4.2 
K28Q - - 
V29Q 430 130 
K31Q 270 100 
N35Q 2.5 - 







K4Q 98 79 
I6Q 190* 180 
E15Q 4.4 3.4 
T17Q - - 
E19Q 1.0 - 
T44Q 1.3 1.5 
D46Q 5.0 27 
T51Q 71 46 
T53Q 3.3 2.6 
T55Q 20 160 
 
Table 1. GB1 Q-library upon fluorescent labeling catalyzed by native MTG. Selectivity 
represents the fold-increase of the ratio of fluorescence in a reaction to non-specific fluorescence 
in the control; the higher the selectivity, the lower the background. Efficiency is the fold-increase 
of the ratio between fluorescence of the GB1 variant to native GB1, labeled in increasingly 
saturated shades of green: 1 to 10-fold, pale green; 10 to 100-fold, bright green; greater than 100-
fold, dark green. Signals that were lower than that of native GB1 are represented with a dash (-), 
and those that could not be accurately quantified due to saturation of the detector are indicated 
with an asterisk (*). N.D. = not detected, N/A = not available. 
GB1 Variant Tm, °C Gln 
Location 
WT 70.3 ± 0.3 α-helix 
Q32N 70.0 ± 0.4 N/A 




T11Q 70.4 ± 1.3 
V21Q 69.5 ± 0.3 
D40Q 69.5 ± 1.1 
E42Q 69.7 ± 1.4  
D47Q 69.8 ± 0.5 
A48Q 69.2  ± 0.7 
T49Q 70.2 ± 0.2 
A24Q 69.8 ± 0.3  
 
α-Helix 
K28Q 70.0 ± 0.2 
V29Q 69.6 ± 0.4 
K31Q 69.6 ± 0.8  
N35Q 69.3 ± 0.2 
D36Q 69.9 ± 0.5 





I6Q 70.1 ± 0.7 
E15Q 69.7 ± 0.1 
T17Q 70.0 ± 1.2 
E19Q 70.0 ± 1.0 
T44Q 69.3 ± 1.1 
D46Q 70.1 ± 0.6 
T51Q 69.9 ± 0.5 
T53Q 70.0 ± 0.7 
T55Q 70.0 ± 0.1 
 
Table 2. Melting temperatures of GB1 variants determined by differential scanning fluorimetry. 
  




Native 25.9 1 
W69G 43.2 1.7-fold 
W69H 43.1 1.7-fold 
Y75G 52.0 2.0-fold 
Y75H 46.6 1.8-fold 
Y302G 70.4 2.7-fold 
Y302H 68.4 2.6-fold 
 






















MTG variant W69 Y75 Y302 
G H G H G H 
GB1 substrate Native 1.0 3.2 1.1 1.0 14 2.1 
I6Q 56 110* 5.1 39 140* 200* 
  
 Efficiency, compared to native MTG 
MTG variant W69 Y75 Y302 
 G H G H G H 
GB1 substrate Native - 2.1 - - 2.5 1.1 
 I6Q - 1.1 - - 1.6 1.6 
      
 Efficiency, compared to native GB1 substrate 
MTG variant W69 Y75 Y302 
 G H G H G H 
GB1 substrate I6Q 230 31 42 80 50 200 
        
  I6Q GB1 substrate, 1 s exposure 
MTG variant  Native W69H Y302G Y302H 
Selectivity  330 170 140 210 
Efficiency  N/A 1.0 2.5 2.5 
 
Table 4. MTG variant reactivity towards native and I6Q GB1. For the top three tables, 
fluorescence was quantified after 5 s of exposure, while the last table quantified after 1 s of 
exposure to prevent saturation of the detector. Selectivity represents the fold-increase of the ratio 
of fluorescence in the reactions over non-specific fluorescence in the control; the higher the 
selectivity, the lower the background. Efficiency is the fold-increase of the ratio of fluorescence 
of the variant relative to native protein and is labeled in increasingly saturated shades of green: 1 
to 10-fold, pale green; 10 to 100-fold, bright green; greater than 100-fold, dark green. Signals 
that were lower than that of native GB1 are represented with a dash (-), and those that could not 









Figure 1. MTG-catalyzed protein crosslinking. 
  
 
Figure 2. Structures of GB1. Native GB1 (top left), as well as the residues which underwent 
glutamine substitution; loop variants (top right), helix variants (bottom left), and sheet variants 
(bottom right). The labeling efficiency of each residue is colored according to the results 
presented in Table 2; grey are inert. 
  
 
Figure 3. Assay used to conjugate GB1 variants with fluorescent probe 1 and representative 
SDS-PAGE analysis of fluorescently labeled GB1 variants. A) GB1’s single glutamine residue is 
targeted by MTG, forming an amide bond with the amine-bearing fluorophore. Excess 
fluorophore is removed by dialysis and reactivity is analyzed using SDS-PAGE. B) Equal 
quantities of protein were loaded and excited for 5 s using a Cy2 excitation filter prior to 
Coomassie Brilliant Blue staining. GB1 variants exhibiting low fluorescent conjugation 
efficiencies were barely visible even after 24 h of reaction time (Native GB1, T9Q; Q32N served 
as a negative control); for this reason, the 2 h reactions were omitted. Red bands indicate 
saturation of the detector. 












Figure 4. Location of residue substitutions in MTG. Left: A top-down surface view into the 
active-site crevice, with W69, Y75, and Y302 colored green, orange, and cyan, respectively. 
Center: cartoon representation with the active site zoomed (right). The catalytic cysteine 
essential for enzymatic activity, shown in yellow, was not mutated. PDB coordinates 1IU4. 
 
 
Figure 5. Primary amino acid sequence alignment of GB1 variants, centered on the glutamine 
residue present in the native or variant GB1s; residue numbering is indicated. Variants are 
ranked according to their reactivity, with the most reactive variant presented first. Amino acids 
are colored according to the properties of their side chains: green = hydrophobic; yellow = polar; 
blue = basic; red = acidic; grey = glycine. 
 
